

Dear editors and reviewers:

Thank you very much for considering our revised manuscript entitled “Reduction rate of M protein as a useful prognostic factor in standard-risk group of newly diagnosed multiple myeloma” (Manuscript NO.: 83820, Case Control Study) .

We appreciate the careful review and constructive comments provided by the reviewers of our manuscript. we hope are suitable for publication in World Journal of Clinical Cases.

No conflict of interest exists in the submission of this manuscript, and manuscript is approved by all authors for publication. I would like to declare on behalf of my co-authors that the work described was original research that has not been published previously, and not under consideration for publication elsewhere, in whole or in part. All the authors listed have approved the manuscript that is enclosed.

Reviewer’s comment:

This is a quality paper. The authors concluded that higher reduction rate of M protein after first and fourth chemotherapy cycles could be favourable prognostic factors. The main flow is a heterogenous group of patients regarding different chemotherapy regimens applied.

Answer:

In this work, we revealed that The reduction rate of M protein after first and fourth cycle chemotherapy as a useful prognostic factor in standard-risk group of newly diagnosed multiple myeloma. I hope this paper is suitable for “World Journal of Clinical Cases” .

We deeply appreciate your consideration of our manuscript. If you have any queries, please don’t hesitate to contact me at the address below.

Thank you and best regards.

Jun-Yu Zhang

Zhejiang Provincial Lishui Municipal Central Hospital

NO.289 Kuocang Road,

Hangzhou, Zhejiang, China

Zip code: 323000

E-mail: zhangjunyu815@163.com